版本:
中国

BRIEF-Biolinerx announces regulatory submission for phase 1B trial of BL-8040

May 22 Bioline Rx Ltd

* Biolinerx announces regulatory submission for phase 1B trial of BL-8040 in combination with atezolizumab in AML

* Trial, named battle, is expected to commence in second half of 2017, following receipt of regulatory approval Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐